Pharmaceuticals in the environment

Novartis is committed to minimizing the environmental impact of its products. Pharmaceuticals entering the aquatic environment are an inevitable consequence of science-based healthcare and our business activity. As scientific knowledge evolves in this field, we regularly benchmark our activities, and also actively support academia, regulators and other stakeholders in developing more efficient risk-management practices.

The levels of active pharmaceutical ingredients found in the aquatic environment as a result of Novartis activities are below those approved as safe by medical regulatory agencies, and we believe that such levels do not present a health risk for humans. Nevertheless we strive to minimize discharges of active pharmaceutical ingredients into wastewater from our operations, and have banned landfilling of any pharmaceutical waste. Such waste is incinerated in approved, state-of-the-art facilities.

Novartis works with third parties to ensure that they are guided by this policy in their waste minimization activities. We have also supported research by a group of German wastewater engineers, making available a selection of in-market medicines, as well as innovative compounds still in development. The aim of this pioneering effort is to demonstrate that affordable, reliable wastewater technology works in practice – and helps remove existing, as well as new, pharmaceuticals from wastewater before they reach the aquatic environment.

Please read the Novartis position on Pharmaceuticals in the Environment
(211 KB)

Learn more about Performance data and target achievement on PiE